Haematologica, Vol 92, Issue 6, 846-849 doi:10.3324/haematol.11072
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pereira, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pereira, A.

Disorders of Hemostasis

Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection

Arturo Pereira

From the Service of Hemotherapy and Hemostasis, Hospital Clínic, Barcelona, Spain

Correspondence: Arturo Pereira, Service of Hemotherapy and Hemostasis, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. E-mail: apereira{at}clinic.ub.es

A probabilistic model was used to compare cryoprecipitate to viral inactivated, commercial fibrinogen concentrate to evaluate with regard to the recipient’s risk of exposure to an emergent AIDS-like epidemic. In patients who occasionally need a therapeutic dose of fibrinogen, commercial fibrinogen would be marginally safer than cryoprecipitate if the new pathogen were sensitive to inactivation. But there is a potential high risk of exposure if the emerging agent withstands inactivation. In most of the analyzed scenarios, cryoprecipitate is safer than commercial fibrinogen as long as the odds that the new agent is sensitive to inactivation are lower than 1.000 to 1.

Key words: transfusion, cryoprecipitate, fibrinogen, infection, risk.




This article has been cited by other articles:


Home page
 haematolHome page
A. Groner
Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
Haematologica, February 1, 2008; 93(2): e24 - e26.
[Full Text] [PDF]

Home page
 haematolHome page
A. Pereira
Reply. Groner A. [Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92:846-9].
Haematologica, February 1, 2008; 93(2): e27 - e27.
[Full Text] [PDF]